\n<\/p>\n
Two companies that<\/span> launched last year with plans to create gene-edited babies have already shut down, citing money issues and internal conflict.<\/p>\n One of them, Manhattan Genomics of New York, closed abruptly shortly after announcing a team of scientific advisers in October that included a prominent fertility doctor, a data scientist who worked for de-extinction company Colossal Biosciences, and a scientist who pioneered a \u201cthree-parent\u201d IVF technique. The other, California-based Bootstrap Bio, said it ceased operations in late 2025, as first reported by Mother Jones.<\/p>\n Manhattan Genomics and Bootstrap Bio had ambitions to edit DNA in human embryos with the goal of preventing serious disease in babies. Known as germline editing, the idea is highly controversial because any changes made at the embryo level would be passed on to future generations. It\u2019s different from gene-editing treatments currently being tested on patients, which only affect the treated individual.<\/p>\n The safety and efficacy of germline editing is also unproven. One concern is that the technology can result in unintended, potentially harmful \u201coff-target\u201d edits. Many researchers worry that permitting embryo editing to address serious diseases will inevitably lead to it being used for enhancement purposes, such as appearance or intelligence, to make \u201cdesigner babies.\u201d It\u2019s currently prohibited in the US and many other countries to initiate a pregnancy with an edited embryo.<\/p>\n There are three known children who were gene-edited as embryos as a part of a now infamous 2018 experiment conducted by Chinese scientist He Jiankui. The revelation shocked the international scientific community, and a Chinese court sentenced He to three years in prison for illegal medical practices. Once taboo, the prospect of gene-edited babies has been recently revived by biotech entrepreneurs, futurists, and Silicon Valley investors. But the path to a viable gene-edited baby business is apparently presenting some challenges.<\/p>\n “We ran out of money. We had some promising results in the lab but I couldn\u2019t get enough investors interested for us to keep our operation going,” Bootstrap Bio CEO and cofounder Chase Denecke told WIRED via email. The company still exists but isn\u2019t actively operating, he added.<\/p>\n Bootstrap has had other problems. In August 2025, federal officers arrested the company\u2019s chief science officer at the time, Qichen Yuan, and charged him with attempted sex trafficking of a child, as Mother Jones reported. Yuan is now set to appear in federal court in Boston. When reached via email, Yuan\u2019s lawyer declined to comment.<\/p>\n Denecke told WIRED that he didn\u2019t know about the charges until after the company \u201cceased active operations.\u201d Yuan worked as a contractor for Bootstrap Bio in 2024 and 2025 until the company shut down, according to Denecke. \u201cWe would have let him go earlier if we had known,\u201d Denecke said over email.<\/p>\n Bootstrap Bio had early interest from investors. In a 2024 LinkedIn post announcing the formation of the startup, for example, Denecke mentioned that a venture capitalist flew him out to Honduras.<\/p>\n Manhattan Genomics, which also went by Manhattan Project, planned to pursue human embryo editing for disease prevention. In a since deleted X post from March, cofounder Cathy Tie said the startup shut down due to a \u201ccofounder conflict.\u201d At the same time, she publicly announced the formation of a new company, Origin Genomics, to advance germline gene correction.<\/p>\n Manhattan Genomics\u2019 cofounder Eriona Hysolli told WIRED that she and Tie parted ways due to \u201cfundamental disagreements stemming from the coexistence of a Cayman-based entity with the same name with separate governance by my cofounder, and which confounded the open and transparent mission of Manhattan Genomics.\u201d<\/p>\n<\/div>\n